Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo biological standardization of Cynodon dactylon allergen extracts
2025-522597-37-00Phase 2Authorised
- Sponsor
- Asacpharma
- Start
- Oct 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cynodon dactylon allergen extract in grass pollen allergy and allergic rhinitis (AR), sponsored by Asacpharma. Primary endpoints: Wheal area after prick test administration, Dose-response relationship and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
Cynodon dactylon allergen extract
03
Conditions
grass pollen allergyallergic rhinitis (AR)
Beyond the preview
Go deeper on 2025-522597-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522597-37-00.